667 related articles for article (PubMed ID: 23479184)
1. Sleep quality and preclinical Alzheimer disease.
Ju YE; McLeland JS; Toedebusch CD; Xiong C; Fagan AM; Duntley SP; Morris JC; Holtzman DM
JAMA Neurol; 2013 May; 70(5):587-93. PubMed ID: 23479184
[TBL] [Abstract][Full Text] [Related]
2. Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease.
Musiek ES; Bhimasani M; Zangrilli MA; Morris JC; Holtzman DM; Ju YS
JAMA Neurol; 2018 May; 75(5):582-590. PubMed ID: 29379963
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.
Vos SJ; Xiong C; Visser PJ; Jasielec MS; Hassenstab J; Grant EA; Cairns NJ; Morris JC; Holtzman DM; Fagan AM
Lancet Neurol; 2013 Oct; 12(10):957-65. PubMed ID: 24012374
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
6. Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.
Villeneuve S; Vogel JW; Gonneaud J; Pichet Binette A; Rosa-Neto P; Gauthier S; Bateman RJ; Fagan AM; Morris JC; Benzinger TLS; Johnson SC; Breitner JCS; Poirier J;
JAMA Neurol; 2018 May; 75(5):608-619. PubMed ID: 29482212
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
8. Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease.
Liguori C; Romigi A; Nuccetelli M; Zannino S; Sancesario G; Martorana A; Albanese M; Mercuri NB; Izzi F; Bernardini S; Nitti A; Sancesario GM; Sica F; Marciani MG; Placidi F
JAMA Neurol; 2014 Dec; 71(12):1498-505. PubMed ID: 25322206
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
[TBL] [Abstract][Full Text] [Related]
10. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.
Vlassenko AG; McCue L; Jasielec MS; Su Y; Gordon BA; Xiong C; Holtzman DM; Benzinger TL; Morris JC; Fagan AM
Ann Neurol; 2016 Sep; 80(3):379-87. PubMed ID: 27398953
[TBL] [Abstract][Full Text] [Related]
11. Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies.
Rådestig MA; Skoog J; Zetterberg H; Kern J; Zettergren A; Sacuiu S; Waern M; Wetterberg H; Blennow K; Skoog I; Kern S
J Alzheimers Dis; 2021; 79(1):225-235. PubMed ID: 33216028
[TBL] [Abstract][Full Text] [Related]
12. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
14. Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls.
Mattsson N; Insel PS; Donohue M; Jagust W; Sperling R; Aisen P; Weiner MW;
JAMA Neurol; 2015 May; 72(5):554-60. PubMed ID: 25775167
[TBL] [Abstract][Full Text] [Related]
15. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.
Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS;
JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267
[TBL] [Abstract][Full Text] [Related]
16. Associations Between β-Amyloid Kinetics and the β-Amyloid Diurnal Pattern in the Central Nervous System.
Lucey BP; Mawuenyega KG; Patterson BW; Elbert DL; Ovod V; Kasten T; Morris JC; Bateman RJ
JAMA Neurol; 2017 Feb; 74(2):207-215. PubMed ID: 27992627
[TBL] [Abstract][Full Text] [Related]
17. Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults.
Handoko M; Grant M; Kuskowski M; Zahs KR; Wallin A; Blennow K; Ashe KH
JAMA Neurol; 2013 May; 70(5):594-9. PubMed ID: 23479202
[TBL] [Abstract][Full Text] [Related]
18. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
Alcolea D; Martínez-Lage P; Sánchez-Juan P; Olazarán J; Antúnez C; Izagirre A; Ecay-Torres M; Estanga A; Clerigué M; Guisasola MC; Sánchez Ruiz D; Marín Muñoz J; Calero M; Blesa R; Clarimón J; Carmona-Iragui M; Morenas-Rodríguez E; Rodríguez-Rodríguez E; Vázquez Higuera JL; Fortea J; Lleó A
Neurology; 2015 Aug; 85(7):626-33. PubMed ID: 26180139
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
